NRC's Q4 Earnings Down Y/Y on High Client Attrition, Stock Falls 27%
NRC Health's Q4 EPS and revenues decline year amid prior client attrition, though recurring contract value grew 8%, pointing to recovery prospects in 2026.
National Research Corporation (NRC) Q4 2025 Earnings Call Prepared Remarks Transcript
National Research Corporation (NRC) Q4 2025 Earnings Call Prepared Remarks Transcript
National Research: The Turnaround Is Invisible Until It Isn't
National Research Corp. is undervalued, trading at a modest multiple despite a clear pivot from contraction to growth. TRCV, NRC's key forward metric, grew 8% YoY, signaling imminent revenue acceleration and a strong 2026 setup. Margins are expanding as cost structure is rationalized; normalized FCF could approach $38M in 2026 after one-off expenses subside.
Nuclear startup that sued NRC raises $130 million with backing from Anduril's Palmer Luckey and senior Palantir executive
Valar Atomics raised $130 million with participation from Anduril Industries founder Palmer Luckey and Palantir Chief Technology Officer Shyam Sankar. Valar is developing reactor technology that uses helium as a coolant and operates at higher temperatures than traditional plants.
NRC Stock Up 12% Despite Q3 Earnings Down Y/Y on Rising Interest Costs
NRC Health's Q3 earnings are impacted by rising interest expenses, but margin gains, cash flow strength and a 33% dividend hike offset these headwinds.
National Research Corporation (NRC) Q3 2025 Earnings Call Prepared Remarks Transcript
National Research Corporation (NASDAQ:NRC ) Q3 2025 Earnings Call October 28, 2025 4:00 PM EDT Company Participants Trent Green - CEO & Director Shane Harrison - Chief Financial Officer Presentation Operator Good afternoon. Thank you for attending the NRC Health Third Quarter 2025 Earnings Call.
NRC's Q2 Earnings Rise Y/Y on Cost Control and TRCV Growth
National Research's Q2 adjusted earnings improved year over year on cost control and TRCV gains, but a one-time executive expense weighed on margins.
NRC Q1 Earnings Dip Y/Y Amid Rising Interest Costs, Shares Up 13%
National Research reports a year-over-year decline in Q1 earnings, pressured by rising interest costs, declining revenues, and higher debt levels amid ongoing sales force expansion.
Amazon-Owned One Medical CEO Trent Green to Move to NRC Health
The CEO of Amazon-owned One Medical, Trent Green, will leave that position to become CEO of National Research Corporation, a publicly traded provider of healthcare solutions doing business as NRC Health. NRC Health announced the move in a Wednesday (March 5) press release, saying Green will join the company June 1.
National Research's Q4 Earnings Drop Y/Y, Stock Falls 9%
NRC's Q4 EPS drops to 28 cents despite revenue growth, hit by rising costs and higher interest expenses.
Zacks Initiates Coverage of NRC Health With Neutral Recommendation
Discover why Zacks has given NRC Health a "Neutral" rating, being the first on Wall Street to initiate coverage on the stock. Dive into the company's AI innovations, strategic partnerships, and financial resilience, along with the challenges of revenue declines, rising debt and stiff competition.
